You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Autologous stem cell transplantation,

Showing 9976 - 10000 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Toxicity Due to Radiotherapy, NSCLC Trial in Hefei (High-dose fractionated radiotherapy, Low-dose fractionated radiotherapy)

Recruiting
  • Toxicity Due to Radiotherapy
  • Non-small Cell Lung Cancer
  • High-dose fractionated radiotherapy
  • Low-dose fractionated radiotherapy
  • Hefei, Anhui, China
    Anhui Provicial Hospital
Mar 7, 2022

COVID-19 Respiratory Infection Trial in Sohag (laboratory test)

Completed
  • COVID-19 Respiratory Infection
  • laboratory test
  • Sohag, Egypt
    Sohag University
Oct 24, 2022

Non Small Cell Lung Cancer Trial in Palo Alto, Sacramento, Stony Brook ([18F]F AraG)

Recruiting
  • Non Small Cell Lung Cancer
  • [18F]F AraG
  • Palo Alto, California
  • +2 more
Apr 11, 2022

Betrnet Stem Cells and Origins of Barrett's Esophagus Project 3

Completed
  • Barrett's Esophagus
  • response to therapy
  • New York, New York
  • +1 more
Dec 13, 2021

Diabetes, Type 1, Diabetic Nephropathy Trial in Worldwide (sirolimus versus mycophenolate mofetil)

Completed
  • Diabetes Mellitus, Type 1
  • Diabetic Nephropathy
  • sirolimus versus mycophenolate mofetil
  • Innsbruck, Austria
  • +13 more
Aug 17, 2021

Leukemia, Lymphoma, Lymphoma, B-Cell Trial in New York (CAR T-Cell Infusion)

Withdrawn
  • Leukemia
  • +2 more
  • CAR T-Cell Infusion
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 4, 2022

Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Tumor

Active, not recruiting
  • Advanced Systemic Mastocytosis
  • +3 more
  • Stanford, California
  • +31 more
Mar 25, 2022

Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Immunonutrition Trial in Hefei (Whole-course Immunonutrition Combined

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • +3 more
  • Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
  • Hefei, China
    Anhui provincial hospital
Apr 16, 2023

Sickle Cell Disease Trial in Pittsburgh (Skin Hydration Sensor)

Recruiting
  • Sickle Cell Disease
  • Skin Hydration Sensor
  • Pittsburgh, Pennsylvania
    UPMC Sickle Cell Clinic
Apr 6, 2022

CML (Chronic Myelogenous Leukemia Trial (KDS-1001)

Not yet recruiting
  • CML (Chronic Myelogenous Leukemia
  • (no location specified)
Jul 27, 2022

Philadelphia Positive, BCR-ABL Positive, Acute Lymphoblastic Leukemia Trial in Italy (Ponatinib)

Completed
  • Philadelphia Positive
  • +2 more
  • Alessandria, Italy
  • +41 more
Nov 18, 2021

Hemophilia A Trial in United Kingdom, United States (SIG-001)

Terminated
  • Hemophilia A
  • SIG-001
  • Indianapolis, Indiana
  • +5 more
Nov 7, 2022

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease Trial in United States (drug, other,

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Minimal Residual Disease
  • Goodyear, Arizona
  • +237 more
Jan 3, 2023

Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous

Suspended
  • Advanced Head and Neck Squamous Cell Carcinoma
  • +17 more
  • Gilbert, Arizona
  • +19 more
Dec 31, 2022

Oncogenic Drivers and Somatic Evolution in the Oral Mucosa

Not yet recruiting
  • Carcinoma, Squamous Cell
  • Oral cytobrush
  • Bougival, France
  • +14 more
Oct 16, 2023

Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer Trial in Worldwide (Durvalumab, Tremelimumab,

Recruiting
  • Unresectable Locally Advanced Urothelial Cancer
  • Metastatic Urothelial Cancer
  • Birmingham, Alabama
  • +237 more
Aug 18, 2022

Lymphomas Non-Hodgkin's B-Cell, Relapse Trial in Tianjin (CD19 CAR T cells)

Completed
  • Lymphomas Non-Hodgkin's B-Cell
  • Relapse
  • CD19 CAR T cells
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jan 24, 2022

B Cell Malignancy Trial in Hefei, Suzhou (ThisCART19 cells)

Recruiting
  • B Cell Malignancy
  • ThisCART19 cells
  • Hefei, Anhui, China
  • +1 more
Dec 20, 2021

Lung Cancer, Lung Tumor Trial in Miami (Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray), Stereotactic Adaptive

Recruiting
  • Lung Cancer
  • Lung Tumor
  • Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray)
  • Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray)
  • Miami, Florida
    Miami Cancer Institute
May 24, 2022

Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Metastatic Neuroendocrine Tumor Trial in

Active, not recruiting
  • Metastatic Large Cell Neuroendocrine Carcinoma
  • +3 more
  • Cabozantinib S-malate
  • +2 more
  • Birmingham, Alabama
  • +46 more
Dec 30, 2022

NSCLC Trial in Nanjing (Fruquintinib,Sintilimab,Pemetrexed,Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Nanjing, Jiangsu, China
    Jiangsu Province Hospital
Feb 11, 2022

NSCLC Trial in Charleston (Sotorasib and Tarloxotinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • Sotorasib and Tarloxotinib
  • Charleston, South Carolina
    Hollings Cancer Center at Medical University of South Carolina
Mar 28, 2022

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Moscow, Russian Federation
      Federal State Budgetary Institution National Medical Research Ce
    Mar 29, 2022

    Lymphoma, Leukemia, Multiple Myeloma Trial in Boston (MEDI-507, Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant)

    Terminated
    • Lymphoma
    • +3 more
    • MEDI-507
    • Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant
    • Boston, Massachusetts
      Massachusetts General Hospital
    Mar 14, 2018

    Head Neck Cancer Trial in Washington (Cisplatinum, Docetaxel, Carboplatin)

    Active, not recruiting
    • Head and Neck Cancer
    • Washington, District of Columbia
      George Washington University-Medical Faculty Associates
    Nov 14, 2022